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Objectives. This study was designed to test the hypothesis that
andarrhythmic drugs that decrease RR variability will predict
all-cause mortality during follow-up after myocardial 11PNrction .
Background. RR variability, a noninvasive indicator of auto-
nomic nervous system activity, predicts death after acute myocar-
dial infarction independently of other risk predictors and changes
substantially in response to some drugs . A previous study in
patients with chronic heart disease and frequent ventricular
premature complexes reported that flecainide decreased vagal
modulation of RR intervals but andodarone did not . The investi-
gators of that study speculated that changes in RR variability
during antiarrhythmic drug therapy predict an increased mortal-
ity rate during long-term drug treatment . To explore this hypoth-
esis further, we compared the effects of encainide and flecainide,
which increase long-term mortality substantially, on RR variabil-
ity with the effects of placebo and moricizine, which have no
significant effect on mortality during long-term treatment of
unsustained ventricular arrhythmias after myocardial infarction.
Who& The 24-h power spectral density was computed from
the baseline electrocardiographic recordings and drug evaluation
tapes, and six frequency domain measures of RR variability were
calculated : ultra-low frequency (<0.0033 Hz), very low frequency
(0 . 33 to <0.04 Q, low frequency (0.04 to <0 .15 Hz) and high
frequency power (0.15 to <0 .40 Hz), plus total power (<0 .40 Hz)
and the ratio of low to high frequency power . Changes in power
spectral measures were related to drug treatment and to mortal-
ity.
RR variability, a noninvasive indicator of autonomic ner-
vous system activity, predicts death after acute myocardial
infarction independently of other risk predictors (1-6) . Un-
like other major risk predictors, such as left ventricular
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Results . In the placebo group, values for RR interval and RR
variability increased because of recovery from the effects of acute
yocardial infarction . Contrasting placebo treatment with all
three active anflarrhythade drug treatments taken together
showed that of all the measures of RR variability, only NNSO,
pNN50 and low frequency power changed significantly during
drug treatment (Bonferroni adjusted p value <0 .025) ; these
variables all decreased during drug therapy . Contrasting encain-
ide and flecainide with moricizine, we found that the encainide
and flecalnide groups taken together showed a larger decrease in
dLF than moricizine, but the dVerence was of borderline signif-
icance (Bonferroni adjusted p value <0.08) . Survival was signif-
icantly worse in the groups treated with encainide and flecainkde
than in the groups treated with placebo or moricizine (relative risk
>2.0, adjusted p < 0.05). The antiarrhythmic drug-induced
change in measures of RR variability was not a significant
predictor of all-cause mortality during a year of follow-up after
myocardial infarction .
Conclusions. Encainide, flecainide and moricizine all caused a
decrease in RR variability in patients studied -1 month after
acute myocardial infarction. Encainide and flecalnide caused a
significant increase in mortality rates ; placebo and moricizine did
not. Baseline measurements of RR variability also predicted
all-cause mortality after myocardial infarction . The decrease in
RR variability produced by the three antiarrhythtnic drugs did
not predict mortality during follow-up .
(J Am Coll Cardiol 1994,23 .*733-40)
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ejection fraction, RR variability is a dynamic variable,
decreasing immediately after myocardial infarction and then
recovering over a few months (7,8) . Also, RR variability
changes substantially in response to some drug! In normal
subjects, RR variability increases in response to atenolol and
digoxin but does not change in response to diltiazem or
enalapril (9,10) . In patients with chronic heart disease and
frequent ventricular premature complexes, Zuanetti et al .
(11) reported that flecainide decreased the vagal modulation
of RR intervals, but amiodarone did not . These investigators
speculated that changes in RR variability that indicate a
decrease in vagal modulation may predict an increased
likelihood of mortality during long-term drug treatment . To
explore this hypothesis further, we compared the effects on
RR variability of encainide and flecairide, which increase
0735-1097/94/$7 .00
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mortality substantially (12,13), with the effects of moricizine,
which has no significant effect on mortality during long-term
treatment of postinfarction unsustained ventricular arrhyth-
mias (14) . Also, we tested the hypothesis that the effect of
drug on RR variability predicted subsequent mortality
.
Methods
Patient selection . To evaluate the effects of encainide,
flecainide and moricizine on RR variability, we used 24-h
electrocardiographic (ECG) recordings from the Cardiac
Arrhythmia Pilot Study (CAPS) (15,16), which recruited
patients in a 6- to 60-day period after acute myocardial
infarction . To qualify, patients had to have 2
:10 ventricular
premature complexes/h on a 24-h continuous ECG recording
(15). After patients were enrolled and baseline data were
obtained, they were randomized to one of five treatment
limbs, four with active antiarrhythmic drug and one with
placebo
. Within the active treatment limbs, drug and dose
changes were permitted to achieve 70% suppression of
ventricular premature complexes 15 . To control for recov-
ery of RR variability as a function of time 8 , we used data
from the group randomized to placebo . To avoid bias due to
drug responsiveness, we used the response to the first dose
of the first drug in three active treatment limbs encainide,
flecainide and moricizine . Imipramine was not evaluated in
this study because there ane no randomized controlled
studies that evaluate its effect on mortality .
Prrocesmsiing of 24-h ECG recordings . The 24-h recordings
were digitized on a Marquette 8000 Hotter system and submit-
ted to the standard Marquette algorithms for QRS labeling and
editing version 5 .8 software . Tile data files were then trans-
ferredd by high speed link from the Marquette scanner to a Sun
workstation where a second stage of editing was done, using
algorithms developed at Columbia University, to find and
correct any remaining errors in QRS labeling that adversely
Wfect measurement of heart period variability . For a tape to be
eligible for this study, we required it to have 2t12 h of
analyzable data and at least half of the night-time 00:00 to
05:00
and daytime
07:30 to 21 :30
periods analyzable
. At least
50% of the recording had to be sinus rhythm .
Power spectral analysis . After editing was completed, the
heart period power spectrum was computed over a 24-h
interval using a previously described method
17, 18 . First, a
regularly spaced time series was derived from the RR
intervals by sampling the irregularly spaced series defined by
the succession of normal RR intervals. For 24-h ECG
recordings, 2"
points were sampl d, A "boxcar" low pass
filter with a window twice the sampling interval was then
applied. Gaps in the time series resulting from noise or
ectopic complexes were filled in by linear splining . A fast
Fourier transform was computed and the resulting power
spectrum was corrected for the attenuating effects of both
the filtering and the sampling
17,18 . The effective lower end
of the frequency range for this method was 1
.16 x 10-5 for
24 h. The upper end of the frequency range was 0
.40 Hz .
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Time and frequency domain measures of heart period
variability . Frequency domain measures of heart period vari-
ability were computed by integrating over their frequency
intervals. Six frequency domain measures were calculated
from spectral analysis of 24 h of RR interval data . We com-
puted the 24-h power spectral , density and calculated the power
within four frequency bands : 1
<0
.0033 Hz = ultra-low
frequency power, 2
0
.0033 to <0 .04 Hz = very low frequency
power, 3
0
.04 to <0 .15 Hz = low frequency power, and 4
0
.15
to 0.40 Hz = high frequency power 5 . In addition, we
calculated total power <0.40 Hz
and the ratio of low to high
frequency power 5 .
In the time domain, we computed NN50, a variable that
reflects vagal modulation of NN intervals, as the number of
differences between successive normal RR intervals exceed-
ing 50 ms. We computed the proportion of differences
between adjacent normal RR intervals that are >50 ins,
pNN50, and the root mean square successive difference, as
described previously 7
Statistical procedures . Before statistical analyses, the
power spectral measures of RR variability were log trans-
formed because their distributions were strongly skewed .
The data were summarized as the mean value ± SD of the
log-transformed data. Baseline
predrug
values were com-
pared among treatment groups by using one-way analysis of
variance for continuous variables and chi-square analysis for
discrete variables . Differences in power between baseline
and initiation of treatment were also compared using one-
way analyses of covariance with two a priori contrasts being
tested : I
placebo versus active antiarrhythmic drug reat
ment, and 2
encainide nd flecainid vers s moricizine
treatment. The two covariates used in these analyses were
time from myocardial infarction to baseline tape and time
from baseline tape to first dosing tape . The Bonferroni
adjustment was used for these multiple contrasts at an
overall alpha level of 0 .05 .
Kaplan-Meier survival analysis. We calculated Kaplan-
Meier curves 19
to display gr ph cally the c mulative
mortality rates of the CAPS patients over the 12-month
period after the 24-h ECG and to test the association
between NN50 and low frequency power measurements and
all-cause mortality . The significance of differences between
curves was evaluated with the log-rank test 20 . For these
analyses, RR variability measures were dichotomized using
cut points obtained from the Multicenter Postinfarction
Program MPIP
p tient groups
5 .
Dichotomization of dNNSO and dLF. The differences in
log-transformed values for NN50 dNN50
or low frequ ncy
power
dLF
between th baseline
drug-free
24-h ECG nd
the 24-h ECG done during treatment were calculated for
each patient . Values for dNN50 and dLF were used as
dichotomous predictors in survival analyses . Dichotomiza-
tion permits an easily understandable relative risk for death
to be calculated from the Cox regression coefficient 21 . The
value at which to dichotomize was determined by calculating
Cox hazard ratios at every possible dichotomizati,,-n point .
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Table 1 . Reasons for Exclusion of 24-h Electrocardiographic
ECG Data
The dichotomization point that yielded the largest hazard
ratio was obtained and rounded to the nearest multiple of
0.1 . Patients with values at or below the dichotomization
point are hypothesized to be at higher risk than patients with
values above it . The P2L BMDP computer program was
used to carry out the Cox survival analyses 22 .
Results
Baseline characteristics of the sample. Table l presents
the reasons why the ECG tapes from 45 of the 400 random-
ized patients could not be used . Overall, 11% of the patients
were excluded from the analysis because of problems with
these tape . There were no differences among the treatment
groups with respect to such exclusion .
Table 2. Comparison of Baseline Clinical Characteristics Among the Treatment Groups n = 355
BIGGER ET AL .
	
735
ANTIARRHYTHMIC DRUGS AND RR VARIABILITY
Table 2 lists the baseline characteristics for the four
treatment groups . The median time from the index myocar-
dial infarction to the baseline 24-h ECG for all four treatment
groups together was 25 days range 5 to 63 . The interval
between the index myocardial infarction and the baseline
24-h ECG did not vary significantly among the four groups .
There was no significant difference among the groups for the
time between the baseline 24-h ECG recording and the first
drug assessment recording. After adjustment for multiple
testing, there were no significant differences at baseline
among the four groups with respect to time or frequency
domain measures of RR variability .
Drug effects on RR interval and RR variability . Table 3
shows the effects of treatment with the first dose of the first
treatment on the 24-h average RR interval and various time
Unless otherwise indicated, values are presented as mean value ± SD or median
range .
Geometric means may be obtained for these values in the original
scale of measurement ms2
by exp mean of the logarithmically transformed values
. The 95% confidence limits for the geometric mean can be calculated by
exp
L ± 1 .96 x SE
, where L is the mean logarithm and SE is the corresponding standard error
. In = natural logarithm
.
Placebo
n = 90
Flecainide
n = 88
Encainide
n = 93
Moricizine
In = 84
Age yr
60 ± 9 59 ± 9
59±9 59±9
Male % 80 80 86
85
CAPS baseline
Previous myocardial infarction
%
32
.2 30 .7 26 .9 27
.4
History of congestive heart failure
4.5 3 .4 6 .5
4 .9
Diabetes
% 15.6 25 .0
17 .2 13 .1
Left ventricular ejection fraction
0.45 ± 0 .12 0 .46 ± 0 .13
0.45±0.12 0 .45 2: 0.14
Rats
% 3.4 7.1
9 .2
7
.5
In ventricular premature complexes/h 4.05 ± 1 .08
4 .03 ± 1 .11
3 .87 ± 1
.20 4 .09 ± 1 .24
Medications %
Digitalis
24 .7 21 .1
19.7 23 .7
Diuretic drug
35 .8 39.4
40.0 43 .4
Beta-adrenergic blocker
43 .2 35
.2 39.5 31 .6
Calcium channel blocker
37 .0 318
44 .6 36 .8
Timing of 24-h ECG recordings
Days from myocardial infarction to baseline tape
24 6-60 17 6-63
30 5-62 31 6-60
Days from baseline tape to the first drug assessment tape 11
6-39 10 6-25
11 6-29
11 4-22
Measures of RR variability
Average normal to normal RR interval
787 ± 147
837 ± 155 849 ± 153
814 ± 135
In ultra-low frequency power ms
2
8 .47 ± 0 .93
8.44 ± 0 .40
8.69±0 .85
8.48±0.94
In very low frequency power ms
2
6.16 ± 1 .30
6 .51 ± 1 .15
6 .53 ± 1 .22 6 .45 ± 1 .09
In low frequency power
ms2 4 .89 ± 1 .38
5 .24 ± 1 .32
5.26±1 .25
5.21±1 .40
In high frequency power
ms 2 3 .95 ± 1 .18
4 .35 ± 1 .25
4 .32 ± 1 .04
4 .35 ± 1 .25
In total power ms
2
8 .64 ± 0.90 8 .66 ± 0
.95
8.88 ± 0.95
8 .69 ± G .94
Ratio of low to high frequency power
3 .35 ± 2 .55
3 .14 ± 2 .20
3 .27 ± 2 .28
3 .09 ± 1 .86
Patient Treatment Group
Placebo
Flecainide Encainide Moricizine
Total
Patients randomized to group 100 103
99 98 400
Reasons for exclusion
ECG tape missing
3 5 2
8 18
ECG tape ineligible 2 6
0 1
9
Patient never had both tapes recorded S 4
4 5 18
Patients remaining for analysis 90 88 93
84 355
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To 3
. Change in Measures of RR Variability Between Baseline and Dosing Tapes
n = 355
Placebo
n = 90
Change in time domain measures of
,r., variability
1 .02
1 .0 .1 .5
1 .55
1 .15,2 .10
1 .59
1 .11,2 .16
Root mean square of successive difference
1 .07
0.98,1 .17
Change in power spectral measures of RR variability
Ultra-low frequency power
1 .06
1 .01 .1
.11
Very low frequency power
1 .12
0.90 .1 .02
Low frequency power
1
.09
1 .0211 16
High frequency power 1 .08
0.99 .1 .17
Total power
1 .06
1 .00 .1 .11
Ratio of low to high frequency power 1 .03
0.90 .1 .18
Average normal to normal RR interval
NNN
pNNNt
and frequency domain measures of RR variability . In the
placebo group, values for RR interval and RR variability
increased because of recovery from the effects of acute myo-
cardial infarction 8 . The increase was larger for NN50 and
pNN50 than for the other measures . Figure I shows the
distribution of changes between the baseline 24-h ECG and the
24-h ECG used to evaluate the first treatment . Using analysis
of covariance procedures and adjusting for time from myocar-
dial infarction to baseline tape and time from baseline tape to
first dosing tape, our a priori contrasts yielded the following
results. Contrasting all three active antiarrhythmic drug treat-
ments taken together with placebo treatment showed that of all
the measures of RR variability, only NN50, pNN50 and low
frequency power changed significantly during drug treatment
Ronferroni adjusted p value <0 .025 . These variables all
decreased during drug therapy . Contrasting encainide and
flecainkle with moricizine, we found that encainide and flecain-
ide taken together caused a larger decrease in dLF than
moricizine, but the difference was borderline Bonferroni ad-
justed p value <0.08 ,
Effect of drug treatment on all-cause mortality. To distin-
guish between the effect of drug and the effect of RR
variability on mortality, we combined into one group pa-
tients on encainide or flecainide and combined into a second
group patients on moricizine or placebo . We grouped pa-
tients receiving encainide and flecainide therapy together
because in the Cardiac Arrhythmia Suppression Trial
I
Flecainide
n = 88
1 .02
0.99 .1 .04
1 .06
0.77,1 .44
IA2
0.73,1 .41
0 .97
0.87,1 .08
Encainide
n = 93
1 .03
I .00, l .04
0 .96
0.71,1 .30
0 .91
0.67,1 .24
III
0.93,1 .09
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Moricizine
n = 84
019
0.97,1 .02
0.78
0
.57,1
.08
0.79
0.58 .1 .08
0.99
0.91,1 .07
IA2 1 .00
1 .01
0 .95 .1 .09 0,95 .1 .05 0,96,1,07
0 .86 0 .96 0.96
0.79 .0 .93 0.92,0.01 1 .06,1 .18
0 .85 0 .96 0 .98
0
.76,0 .93 0.89 .1 .00 0.90 .1 .06
0 .99 1 .05 0.99
0 .89,1 .09 0.97.1 .12 0.92 .1 .07
1 .00 1 .00 1 .00
0.93,1 .07 0.95,1 .04
0.95A -0i
0 .70
0 .80 0 .97
0 .60,0.81 0.71,0 .90 0.87 .1 .08
The number of differences between adjacent normal RR intervals that are >50 ms
. tThe proportion of differences
between adjacent normal RR intervals that
are >50 ms . Quantities not in parentheses are antilogarithms of mean differences between logarithmically transformed dosing tape and baseline tape values that
is, proportional changes ; 1 .06 can be read as a 6% increase and 0.94 as a 6% decrease. The values in parentheses are the corresponding 95%
confidence limits .
The 95% confidence limits were calculated by exp L ± 1% x SE , where L is the mean of the differences between
the logarithm during drug therapy and the
logarithm of the baseline value and SE is the standard error of the differences .
CAST 13 these drugs were associated with similar in-
creases in mortality rates over those associated with placebo
treatment. We grouped patients receiving placebo and mor-
icizine together because in CAST 11 14 such patients had
similar mortality rates during long-term treatment . Figure 2
compares the cumulative mortality rate for the flecainide-
encainide group with that of the placebo-moricizine group in
the CAPS sample . The I-year mortality rate for the placebo-
moricizine group was 6 .4% compared with 12 .3% for the
encainide-flecainide group.
NNSO or low frequency power, as measured on the
baseline or first dosing 24-h ECG, predict all-cause mortality
during follow-up? Kaplan-Meier curves were calculated
Fig. 3 to show the cumulative mortality rate for patients
with high and low frequency power left and high and low
NN50 right measured in the baseline recordings . The cut
points for low frequency power and low NN50 were deter-
mined by using the MPIP data 5 . For both baseline mea-
sures of RR variability, there was a large and statistically
significant difference in the cumulative mortality rate be-
tween the high and low groups p < 0.01 by the log-rank
test . Figure 4 shows that during antiarrhythmic drug treat-
ment, low values for low frequency power left and low
NN50 right still predict all-cause mortality over the year of
follow-up. However, the association between treatment val-
ues of NN50 and mortality is weaker than the association
between baseline values of NN50 and mortality .
JACC Vol . 23, No . 3
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Figure 1 . Effect of antiarrhythmic drugs on dLF
top and
dNN50 bottom . The X axis is the change in the measure of
RR variability in units of natural logarithms
. The Y axis is
the probability density function for a normal distribution
with the same mean and standard deviation as found in the
Cardiac Arrhythmia Pilot Study 15,16
sample . These
curves are centered at the wean values of the distributions
for the four treatment groups
. placebo, moricizine, encain-
ide and flecainide . For the placebo group, the average
change is positive
; for the three groups treated with active
drug, the average change is much less positive or negative .
Dichobamizrltien of dNN50
and F. The value of dQ30
at the optimal dichotomization point, rounded to the nearest
multiple of 0. 1, was -1 .3; 13 .2% of patients had values at or
below the cut point and 86 .8% had values above the cut
point. The value of dLF at the optimal dichotomization
point, rounded to the nearest multiple of 0 .1, was -0.7 .
Using this value, 15 .2% of patients had values at or below
the cut point and 84 .8% had values above it .
Does the change in RR variability drc to anflarrPythmic
drug treatment predict all-cause me . tality during follow-up?
Because we had only 34 end points, we restricted the
analyses to the evaluation of two measures of RR variability
as predictor variables and to one end point, namely, all-
cause mortality . The dNN50 value was chosen because it
decreased significantly during antiarrhythmic drug therapy
and was the study variable used that suggested the primary
hypothesis that we are testing 11 . We chose dLF power
because low frequency power was the only power spectral
measure that decreased significantly during drug treatment,
0.0
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Figure 2 . Comparison of mortality in the group treated with flecain-
ide or encainide RE and the group treated with placebo or
moricizine
P/M
. The mortality rate was 1 .9 times higher in the
flecainide-encainide group p < 0.05 compared with the placebo-
moricizine group . The numbers of patients at the start of follow-up
and the numbers known to be alive and being followed up after 6
months and I year are as follows : flecainide-encainide group 181,
171 and 131, placebo-moricizine group 174, 169 and 131, respec-
tively .
	
	 i
Months of Follow-up
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adjusting for time from myocardial infarction to baseline
tape and time from baseline tape to first dosing tape .
Kaplan-Meier curves were calculated Fig. 5 to show the
cumulative moiWity rates in the groups categorized by the
response of low frequency power or NN50 to drug therapy .
Neither dLF power nor dNN50 had predictive value for
mortality .
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Figure 3. Left, Kaplan-Meier curves compar-
ing the cumulative all-cause mortality rate for
the group with low values of low frequency
power <35 ms measured on the baseline
24-h electrocardiogram ECG with the group
with high values of low frequency power g35
ms- . The number of patients at the start of
follow-up and the number of patients known
to be alive and being followed up after 6
months and I year are as follows : group with
high values of low frequency power 312, 302
and 237; group with low values of low fre-
quency power 43, 38 and 25, respectively .
Right, Kaplan-Meier curves comparing the
cumulative all-cause mortality for the group
with low values for NN50 <800 measured
on the baseline 24-h ECG with the group with
high values of NNSO :2:800 . The numbers of
patients at the start of follow-up and the
numbers known to be alive and being fol-
lowed up after 6 months and I year are as
follows: group with high values of NN50 273,
264 and 208; group with low values of NN50
82, 76 and 54, respectively . There is a large
and significant diflerence between the groups
wish low values for low frequency power or
NN50 and the groups with high values .
DISCUSS%
Drugs with class I antlarrhythrult action decrease NN50 .
Previous invesfigaiors 7,23 showed that NN50 is a sensi-
tive and reliable index of cardiac parasympathetic activity .
In 1991 . ZuaneW et al . 11 published a study that evaluated
three issues: 1 the reproducibility of NN50 in patients with
Figure 4. Left . Kaplan-Meier curves com-
paring the cumulative all-cause mortality for
the group with low values of low frequency
LF power <35 ms measured on the first
24-h electrocardiogram ECG during treat-
ment with the group with high values of low
frequency power 2t35 ms - . The numbers of
patients at the start of follow-up and the
numbers known to be alive and being fol-
lowed up after 6 months and 1 year are as
follows : group with high values of low fre-
quency power 312, 302 and 237; group with
low values of low frequency power 43, 38
and 25, respectively . Right. Kaplan-Meier
curves comparing the cumulative all-cause
mortality for the group with low values of
NN50 <800 measured on the first 24-h
ECG during treatment with the group with
high values of NNSO ?800 , The numbers
of patients at the start of follow-up and the
numbers known to be alive and being fol-
lowed up after 6 months and l year are as
follows : group with high values of NN50
273, 264 and 208 ; group with low values of
NN50 82, 76 and 54, respectively . The mor-
tality rate is substantially higher for the groups
with low values for low frequency power or
NN50. The difference is significant for low
frequency power and borderline for NN50 .
JACC Vol . 23 . No . 3
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Figure S . Left, Kaplan-Meier curves compar-
ing the cumulative all-cause mortality for the
group with low values of dLF <-0.70 In ms~
the difference between baseline values and
the values found in the first 24-h electrocar-
diogram [ECG] during treatment with the
group with high values dLF >-0.70 In ms .
The numbers of patients at the start of fol-
low-up and the numbers known to be alive
and being followed up after 6 months and 1
year are as follows : group with high values for
dLF 312, 302 and 237 ; group with low values
for dLF 43, 38 and 25, respectively . Right,
Kaplan-Meier curves comparing the cumula-
tive all-cause mortality for the group with low
values of dNN50 <-1 .3 In counts measured
on the first 24-h ECG during treatment with
the group with high values of NN50 `-1 .3 In
counts . The numbers of patients at the start
of follow-up and the numbers known to be
alive and being followed up after 6 months and
1 year are as follows : group with high values
of NNSO 273, 264 and 208, group with low
values of NN50 82, 76 and 54, respectively .
The association between dLF or dNN50 are
all-cause mortality is not statistically signifi-
cant . Furthermore, there is a tendency for the
"low risk group" to have a higher !-year
mortality rate .
frequent ventricular premature complexes, 2 the effect of
arrhythmia suppression on NN50, and 3 the link between
antiarrhythmic drug action and its effect on NN50 . They
found that NN50 for a 24-h period was reproducible between
tapes recorded at a median interval of 192 days range 8 to
910 and that the effect of three antiarrhythmic drugs on
NN50 was independent of their effect on the frequency of
ventricular premature complexes . Also, in 56 patients, they
found substantial differences among the three antiarrhythmic
drugs with respect to effect on NN50. For amiodarone, the
median percent change in NN50 was -8% a change that
was not significantly different from baseline values . For two
drugs with class IC antiarrhythmic action, flecainide and
propafenone, the median percent changes were -56% and
-64%, respectively . These workers gave a sophisticated
discussion of how antiarrhythmic drugs might decrease
NN50. They cited work in animal models that suggested that
ventricular arrhythmias could increase efferent sympathetic
activity 24,25 , an effect that would reduce NN50 . Their
data did not support a hypothesis that ventricular arrhyth-
mias cause a decrease in NN50 because there was no
correlation between NN50 and the frequency of ventricular
premature complexes at baseline and NN50 was not affected
when ventricular arrhythmias were suppressed . They spec-
ulated that drugs might interact with the autonomic nervous
system directly or indirectly by means of autonomic reflexes
activated by drug-induced decreases in cardiac contractility
or peripheral vasodilation .
Drug-induced changes on NNSO hypothesized to predict
death. Zuanetti et al . 11 speculated that because low
values for measures of RR variability have been associated
BIGGER ET AL
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with an increased mortality rate after myocardial infarction
1-5 , the decrease in NN50 found during flecainide and
propafenone treatment might reflect a poor prognosis ; that
is, a drug-induced decrease in NN50 might be an indicator of
an increased mortality risk during treatment . They pointed
out that flecainide therapy was associated with increased
mortality rates in CAST 12,13 . Following this line of
reasoning, Recainide and propafenone would be expected to
be harmful and amiodarone not harmful .
Flecainide, encainide and moricizine all decrease NNSO and
low frequency power . We conducted our study in the CAPS
sample to test the hypothesis put forward by Zuanetti et al .
11 . We studied the three drugs that have a known effect on
all-cause mortality . In CAST 12,13 , flecainide and encain-
ide were found to increase the mortality rate during long-
term therapy in a randomized comparison with placebo-
treated control patients . Moricizine-treated patients had a
mortality rate during long-term therapy that was not signif-
icantly different from that in the placebo-treated control
patients 14 . We showed that compared with placebo treat-
ment and adjusted for the recovery in measures of RR
variability that occurs after acute myocardial infarction 8 ,
all three antiarrhythmic drugs caused a decrease in various
measures of RR variability . We selected two measures,
NN50 and low frequency power, for the formal test of our
hypothesis . dNN50 was chosen because NN50 was the
variable used in the study that suggested the primary hy-
pothesis that we are testing and it decreased significantly
during antiarrhythmic drug therapy ; dLF power was chosen
because low frequency power was the only power spectral
measure that decreased significantly during drug treatment .
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Between the two 24-h ECG recordings, there was a 55%
increase in NN50 in the placebo group Table 3
due to the
recovery that takes place after infarction 8 . Relative to the
placebo group, the drug groups showed a decrease in NN50
that was 49%, 59% and 77% for flecainide, encainide and
moricizine, respectively . Between the two 24-h ECG record-
ings, one at baseline and one during drug therapy, there was
a 9% increase in low frequency power in the placebo group .
Relative to the placebo group, the drug groups showed a
decrease in low frequency power that was 24%, 13% and
11% for flecainide, encainide and moricizine, respectively .
Thus, all three drugs caused a decrease in NN50 and in low
frequency power.
gr1 in NNSO or low firequency power
do predict death. As expected from previous studies
1-5,26 in other postinfarction samples, baseline values of
low frequency power and NN50, which reflect the severity
of circulatory dysfunction, were excellent predictors of
all-cause mortality after myocardial infarction . The placebo.
moricizine group had a significantly lower mortality rate than
did the flecainide-encainide group . Also, the values of low
frequency power and NN50 found during antiarrhythmic drug
therapy predicted mortality during the 1st year of follow-up .
However, the decrease in NN50 and low frequency power
caused by drug treatment that is, the difference between the
first drug treatment tape and the baseline tape was not
associated with the mortality rate during a year of treatment .
This suggests that although encainide and flecainide are
associated with an increased mortality rate and a decrease in
NN50 and low frequency power, and although the baseline
values and treatment values for low frequency power and
NN50 are excellent predictors of mortality, the increased
mortality rate is not mediated by the drug-induced changes
in RR variability. Thus, it appears for the three drugs studied
that the decrease in NN50 or low frequency power due to
antiarrhythmic drug therapy itself was not a significant
predictor of mortality .
The current findings indicate that the changes in NN50
and low frequency power caused by treatment with flecain-
ide, encainide or moricizine cannot be used to predict death
during a year of treatment with these drugs . This finding
does not mean that drug-induced changes in measures of RR
variability do not have prognostic significance in other
disease states or for other drugs . However, it indicates that
relations between drug effects on RR variability and out-
comes will have to be established in data sets that have
outcome data available .
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